Nimotuzumab in combination with chemotherapy for patients with malignant gliomas

Chinese Journal of Oncology

Volumn 33, Issue 3, 2011, Pages 232-235

  Yang, Qun Ying ^a   Shen, Dong ^a   Sai, Ke ^a   Mu, Yong Gao ^a   Jiang, Xiao Bing ^a   Zhang, Xian Heng ^a   Chen, Zhong Ping ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Drug therapy; Epidermal growth factor receptor; Gliomas; Nimotuzumab

Indexed keywords

CISPLATIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NIMOTUZUMAB; NIMUSTINE; TEMOZOLOMIDE; TENIPOSIDE;

ACNE; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; DRUG EFFICACY; DRUG TOLERABILITY; GLIOBLASTOMA; HUMAN; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; NAUSEA; NEUTROPENIA; PROGRESSION FREE SURVIVAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; VOMITING;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASTROCYTOMA; CHILD; CISPLATIN; DACARBAZINE; DISEASE-FREE SURVIVAL; FEMALE; GLIOBLASTOMA; GLIOMA; HUMANS; INFUSIONS, INTRAVENOUS; MALE; NAUSEA; NEUTROPENIA; NIMUSTINE; TENIPOSIDE; THROMBOCYTOPENIA; YOUNG ADULT;

EID: 80053424870     PISSN: 02533766     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0253-3766.2011.03.018     Document Type: Article

References (12)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med, 2005, 352:987-996. (Pubitemid 40349501)
2. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol, 2009, 10:459-466.
3. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature, 2008, 455:1061-1068.
4. Ramos TC, Figueredo J, Catala M, et al. Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial. Cancer Biol Ther, 2006, 5:375-379.
5. Lam C, Bouffet E, Bartels U. Nimotuzumab in pediatric glioma. Future Oncol, 2009, 5:1349-1361.
6. Brown PD, Krishnan S, Sarkaria JN, et al. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol, 2008, 26:5603-5609.
7. Brandes AA, Tosoni A, Cavallo G, et al. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperative di neuro-oncologia (GICNO). Br J Cancer, 2006, 95:1155-1160. (Pubitemid 44658477)
8. Wick A, Felsberg J, Steinbach JP, et al. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol, 2007, 25:3357-3361. (Pubitemid 47325623)
9. Kong DS, Lee JI, Kim JH, et al. Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma. Neuro Oncol, 2010, 12:289-296.
10. Perry JR, Bélanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol, 2010, 28:2051-2057.
11. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol, 2007, 25:4722-4729. (Pubitemid 350086473)
12. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med, 2005, 353:2012-2024. (Pubitemid 41609094)